Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Trial Profile

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs CB 839 (Primary) ; Docetaxel; Erlotinib; Everolimus; Paclitaxel
  • Indications Advanced breast cancer; Breast cancer; Gastrointestinal stromal tumours; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 05 Dec 2017 According to a Clathira Biosciences media release, as of October 23, 2017, 49 triple negative breast cancer patients had been treated with doses of CB-839 of 400, 600 or 800 mg bid in combination with 80 mg/m2 IV paclitaxel, weekly, three weeks out of four.
    • 05 Dec 2017 Results from patients with triple negative breast cancer published in a Calithera Biosciences media release.
    • 05 Dec 2017 According to a Clathira Biosciences media release, updated data from the study in patients with triple negative breast cancer will be presented at the 2017 San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top